Viread

DRUG5 trials

Sponsors

Gilead Sciences, Jazz Pharmaceuticals, Replicor Inc., Chong Kun Dang Pharmaceutical, Antios Therapeutics, Inc

Conditions

Chronic Hepatitis BHIV InfectionsHealthyHepatitis B, ChronicHepatitis D

Phase 1

A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers

CompletedNCT01080820

Jazz PharmaceuticalsHealthy

Start: 2010-06-30End: 2010-12-31Target: 36Updated: 2011-07-04

Phase 2

REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection

CompletedNCT02565719

Replicor Inc.Chronic Hepatitis B

Start: 2016-03-31End: 2019-05-31Updated: 2019-09-10

A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection

TerminatedNCT04847440

Antios Therapeutics, IncHepatitis B, Chronic, Hepatitis D

Start: 2021-03-30End: 2022-09-01Updated: 2022-11-18

Phase 3

Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet

Chong Kun Dang PharmaceuticalChronic Hepatitis B

Start: 2016-04-30End: 2018-03-31Target: 158Updated: 2016-06-21

Phase 4

Safety Study of Once a Day ART and Opiate Substitute.

CompletedNCT00324688

Gilead SciencesHIV Infections

Start: 2003-03-31End: 2006-06-30Target: 60Updated: 2014-03-12

Related Papers

Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure

Hepatology Communications2023-07-1713 citations

A randomized phase 1b trial of the active site polymerase inhibitor nucleotide <scp>ATI</scp>‐2173 in patients with chronic hepatitis B virus infection

Journal of Viral Hepatitis2022-10-069 citations

Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP‐Based Therapy

Hepatology Communications2021-07-1020 citations

Benefit of transaminase elevations in establishing functional cure of HBV infection during nap‐based combination therapy

Journal of Viral Hepatitis2021-02-0915 citations

Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy

Gastroenterology2020-03-05218 citations

Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection

PLoS ONE2016-06-03176 citations